Telmisartan Jubilant
Angiotensin II Receptor Blocker (ARB) for High Blood Pressure and Cardiovascular Protection
Quick Facts About Telmisartan Jubilant
Key Takeaways About Telmisartan Jubilant
- Longest-acting ARB: Telmisartan has a half-life of approximately 24 hours, providing the most sustained blood pressure control of any angiotensin receptor blocker, including the critical early morning hours when cardiovascular risk peaks
- Proven cardiovascular protection: Large outcome trials (ONTARGET, PRoFESS) have demonstrated that telmisartan reduces the risk of cardiovascular death, heart attack, and stroke in high-risk patients
- Rare dry cough: Unlike ACE inhibitors, telmisartan very rarely causes a dry cough, making it an excellent alternative for patients who cannot tolerate ACE inhibitors
- Pregnancy is strictly contraindicated: Telmisartan must not be used during the second and third trimesters of pregnancy due to risk of serious fetal harm; use in the first trimester is also not recommended
- Caution with potassium: Avoid potassium supplements and salt substitutes containing potassium, as telmisartan can raise blood potassium levels (hyperkalaemia)
What Is Telmisartan Jubilant and What Is It Used For?
Telmisartan Jubilant is an angiotensin II receptor blocker (ARB) that relaxes blood vessels and lowers blood pressure. It is prescribed to treat essential hypertension in adults and to reduce the risk of cardiovascular events (heart attack, stroke, cardiovascular death) in patients aged 55 years and older who are at high cardiovascular risk.
Telmisartan belongs to a class of medicines called angiotensin II receptor blockers (ARBs), also known as angiotensin receptor antagonists or sartans. It works by selectively blocking the AT1 receptor for angiotensin II, a powerful hormone that constricts blood vessels and stimulates the release of aldosterone (a hormone that causes the body to retain sodium and water). By blocking the effects of angiotensin II, telmisartan allows blood vessels to relax and widen, which reduces peripheral vascular resistance and lowers blood pressure.
In essential hypertension, telmisartan is used as first-line or add-on therapy. Lowering blood pressure with telmisartan has been shown in numerous randomised controlled trials to reduce the long-term risk of stroke, myocardial infarction, heart failure, chronic kidney disease, and cardiovascular death. The European Society of Cardiology (ESC), American Heart Association (AHA), and the UK National Institute for Health and Care Excellence (NICE) all recommend ARBs such as telmisartan as one of the cornerstones of modern antihypertensive therapy.
For cardiovascular risk reduction, telmisartan is indicated in adults aged 55 years or older with manifest atherothrombotic cardiovascular disease (history of coronary artery disease, stroke, transient ischaemic attack, or peripheral artery disease) or in patients with type 2 diabetes mellitus with documented end-organ damage. The landmark ONTARGET trial demonstrated that telmisartan provides cardiovascular protection comparable to the ACE inhibitor ramipril, with better tolerability and a lower rate of discontinuation due to side effects.
Telmisartan Jubilant 20 mg is typically used as a starting dose in patients who are particularly susceptible to blood pressure reductions, such as elderly patients, those with volume depletion, or patients with mild hepatic impairment. For most adult patients, the dose is subsequently titrated upwards to 40 mg or 80 mg once daily according to blood pressure response. The 20 mg strength is also a convenient formulation for gradual dose initiation and for paediatric or special populations under specialist supervision.
Telmisartan has a unique pharmacological property among ARBs: partial PPAR-γ (peroxisome proliferator-activated receptor gamma) agonist activity. This may contribute to modest favourable effects on glucose and lipid metabolism, although telmisartan is not approved as an antidiabetic medication. Its cardiovascular protective effects in diabetic patients, however, are well established through the ONTARGET and PRoFESS trials.
What Should You Know Before Taking Telmisartan Jubilant?
Before starting Telmisartan Jubilant, inform your doctor about all your medical conditions, especially pregnancy, liver disease, kidney disease, diabetes, heart failure, and any other medications you are taking. Telmisartan is contraindicated in pregnancy (second and third trimesters), severe hepatic impairment, and biliary obstructive disorders.
Contraindications
You should not take Telmisartan Jubilant if any of the following apply to you:
- Allergy to telmisartan or to any of the excipients listed in the product information – symptoms may include rash, itching, swelling of the face or throat, or difficulty breathing
- Second and third trimesters of pregnancy – ARBs can cause serious fetal harm including renal failure, oligohydramnios, skull ossification defects, and death
- Biliary obstructive disorders – telmisartan is excreted almost entirely via bile, so obstruction may lead to drug accumulation
- Severe hepatic impairment (Child-Pugh class C) – impaired hepatic clearance can cause unpredictable drug levels
- Concurrent use of aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (eGFR < 60 mL/min/1.73 m²) – dual blockade of the renin-angiotensin system increases risk of hypotension, hyperkalaemia, and renal deterioration
Warnings and Precautions
Talk to your doctor or pharmacist before taking Telmisartan Jubilant if you have or have had any of the following conditions:
- Renal impairment or kidney transplant – dose adjustment is generally not needed in mild-to-moderate impairment, but careful monitoring of potassium and kidney function is recommended; experience in recent kidney transplant recipients is limited
- Bilateral renal artery stenosis or renal artery stenosis in a solitary functioning kidney – risk of severe hypotension and acute renal failure
- Mild-to-moderate hepatic impairment – start with the lowest dose (20 mg) and monitor liver function
- Heart failure or ischaemic cardiomyopathy – your blood pressure-lowering response may be pronounced, particularly after the first dose
- Aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy – use with caution
- Primary aldosteronism – typically unresponsive to ARBs; telmisartan is not recommended as first-line therapy
- Volume or sodium depletion (e.g. from vomiting, diarrhoea, or intensive diuretic therapy) – correct fluid and salt balance before starting telmisartan or use a lower starting dose
- Hyperkalaemia – risk factors include renal impairment, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, or ACE inhibitors
- Diabetes mellitus – telmisartan may affect glucose homeostasis; blood glucose should be monitored closely, especially when starting treatment
- Elderly patients – no specific dose adjustment based on age alone, but start at the lowest dose and titrate cautiously
Use in Children and Adolescents
The safety and efficacy of telmisartan in children and adolescents under 18 years of age have not been established. Available data are insufficient to support a recommended dose in this population. If telmisartan is considered necessary in exceptional circumstances (e.g. paediatric nephrology), it should only be prescribed by a specialist under close clinical and laboratory monitoring.
Pregnancy and Breastfeeding
Telmisartan is contraindicated during the second and third trimesters of pregnancy and should not be used in the first trimester either. ARBs are associated with serious fetal and neonatal complications including hypotension, renal failure, oligohydramnios (reduced amniotic fluid), fetal skull hypoplasia, limb contractures, and intrauterine or neonatal death. Women of childbearing potential should use effective contraception while taking telmisartan. If you become pregnant or plan to become pregnant, stop telmisartan immediately and contact your doctor so that an alternative blood pressure medication (such as labetalol, nifedipine, or methyldopa) can be prescribed.
It is not known whether telmisartan passes into human breast milk; however, its high lipophilicity and extensive biliary excretion suggest that small amounts may be excreted. Because of the potential for serious adverse reactions in nursing infants, and because alternative antihypertensives with better-established safety during lactation are available, telmisartan is not recommended during breastfeeding. Your doctor will recommend a more suitable alternative.
Driving and Operating Machinery
Telmisartan can cause dizziness, fatigue, or rarely syncope (fainting), particularly at the beginning of treatment, after a dose increase, or when standing up quickly (orthostatic hypotension). If you experience these symptoms, you should not drive, cycle, or operate heavy machinery until the symptoms have resolved. Consult your doctor if dizziness or fatigue persists beyond the first few days of treatment.
Food, Alcohol, and Fluid Intake
Telmisartan can be taken with or without food. Food has only minor effects on its absorption and bioavailability. Alcohol may enhance the blood pressure-lowering effect and increase the risk of dizziness, especially during treatment initiation; patients should limit alcohol intake. Maintain adequate but not excessive fluid intake. Dehydration, heavy sweating, vomiting, or diarrhoea can amplify the hypotensive effect – seek medical advice if you cannot maintain normal fluid intake.
How Does Telmisartan Jubilant Interact with Other Drugs?
Telmisartan Jubilant can interact with several medicines, most notably lithium, potassium-sparing diuretics, NSAIDs, other agents affecting the renin-angiotensin system, and digoxin. Always tell your doctor about all medications you take, including over-the-counter drugs, herbal products, and dietary supplements.
Unlike many cardiovascular drugs, telmisartan is not significantly metabolised by cytochrome P450 (CYP) enzymes. It is conjugated with glucuronic acid and excreted almost entirely unchanged in the faeces via biliary excretion. As a result, telmisartan has a relatively clean pharmacokinetic interaction profile. However, important pharmacodynamic interactions still occur, particularly with drugs that affect blood pressure, potassium levels, or kidney function. The following tables summarise the clinically important interactions.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Aliskiren | Direct renin inhibitor | Dual RAS blockade increases risk of hypotension, hyperkalaemia, and renal failure | Contraindicated in diabetic patients or those with eGFR < 60 mL/min; avoid in others |
| ACE inhibitors (e.g. ramipril, lisinopril) | Antihypertensive (RAS inhibitor) | Dual blockade of the renin-angiotensin system – increased risk of hypotension, hyperkalaemia, and acute kidney injury | Combination generally not recommended; avoid unless specifically directed by a specialist |
| Lithium | Mood stabiliser | Telmisartan reduces lithium excretion, leading to potentially toxic lithium blood levels | Monitor serum lithium concentrations closely; dose adjustment usually necessary |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Diuretic | Additive potassium retention – risk of severe hyperkalaemia, especially in diabetes or renal impairment | Monitor serum potassium regularly; use combination with caution |
| Potassium supplements / salt substitutes | Supplement | Elevated serum potassium (hyperkalaemia) | Avoid unless under specific medical supervision with monitoring |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, high-dose aspirin >3 g/day) | Pain relief / anti-inflammatory | Reduced antihypertensive effect; increased risk of acute kidney injury, particularly in dehydrated or elderly patients | Use the lowest effective NSAID dose for the shortest time; monitor renal function and hydration |
| Digoxin | Cardiac glycoside | Telmisartan may increase median digoxin peak plasma concentrations by approximately 49% and trough concentrations by 20% | Monitor digoxin levels; adjust dose as required |
| Other antihypertensives (thiazide diuretics, calcium channel blockers, beta-blockers) | Blood pressure medication | Additive blood pressure lowering | Combinations are often therapeutic and beneficial; fixed-dose combinations with hydrochlorothiazide or amlodipine are widely available |
| Ciclosporin / Tacrolimus | Immunosuppressant | Increased risk of hyperkalaemia and renal impairment | Monitor serum potassium and renal function closely |
| Warfarin | Anticoagulant | Small decrease in mean warfarin trough plasma concentration; INR generally unaffected clinically | Routine INR monitoring; no specific dose adjustment required |
| Antidiabetic drugs (insulin, sulfonylureas) | Glucose-lowering | Telmisartan may modestly improve insulin sensitivity, potentially increasing the risk of hypoglycaemia | Monitor blood glucose, especially at treatment initiation or dose change |
| Corticosteroids (systemic) | Anti-inflammatory / immunosuppressant | May reduce the antihypertensive effect due to sodium and fluid retention | Monitor blood pressure; may need dose adjustment of telmisartan |
Telmisartan is frequently and safely combined with other classes of antihypertensive medications to achieve blood pressure targets. The most common rational combinations include telmisartan plus a thiazide diuretic (such as hydrochlorothiazide) or telmisartan plus a dihydropyridine calcium channel blocker (such as amlodipine). These combinations provide complementary mechanisms of blood pressure reduction and, in the case of ARB + CCB, help offset peripheral oedema associated with CCBs.
What Is the Correct Dosage of Telmisartan Jubilant?
The usual starting dose for hypertension is 40 mg once daily. Telmisartan Jubilant 20 mg is used as a low starting dose in volume-depleted, elderly, or hepatically impaired patients, or when a gradual titration is preferred. Take the tablet at the same time each day with a glass of water, with or without food.
Always take Telmisartan Jubilant exactly as your doctor has told you. Swallow the tablet whole with a glass of water. Do not chew, crush, or break the tablet. You may take telmisartan at any time of day, but it is best to take it at the same time each day to maintain a consistent blood level.
Adults – Essential Hypertension
Standard Hypertension
Usual starting dose: 40 mg once daily
Low starting dose (Telmisartan Jubilant 20 mg): Appropriate for patients who are volume-depleted, on diuretics, elderly, or with mild-to-moderate hepatic impairment
Maintenance dose: 20–80 mg once daily; dose titrated to blood pressure response
Maximum dose: 80 mg once daily
Full antihypertensive effect is generally attained 4–8 weeks after starting treatment or a dose increase. If the target blood pressure is not reached with telmisartan alone, a diuretic (such as hydrochlorothiazide) or another antihypertensive may be added.
Adults – Cardiovascular Prevention
Cardiovascular Risk Reduction (age ≥ 55 years, high cardiovascular risk)
Recommended dose: 80 mg once daily
The 20 mg strength is not typically used as monotherapy for this indication. Patients with existing cardiovascular disease should have blood pressure monitored closely during dose titration. Additional blood pressure-lowering treatment may be required if hypertension persists despite telmisartan.
Children and Adolescents
Telmisartan is not recommended for use in children and adolescents below 18 years of age because of insufficient data on safety and efficacy. If use is considered necessary by a paediatric specialist, doses should be individualised and closely monitored.
Elderly Patients
No dose adjustment is required based on age alone. However, telmisartan should be introduced cautiously in elderly patients, as they are more likely to have age-related reductions in renal or hepatic function, concomitant cardiovascular disease, or polypharmacy. Starting with Telmisartan Jubilant 20 mg and titrating upwards as needed is a sensible strategy in this population.
Patients with Renal Impairment
Patients with mild-to-moderate renal impairment generally do not require dose adjustment, but regular monitoring of serum potassium and creatinine is recommended. Experience in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) is limited, and a lower starting dose (20 mg) should be considered. Telmisartan is not removed by haemodialysis.
Patients with Hepatic Impairment
In patients with mild-to-moderate hepatic impairment (Child-Pugh class A or B), the dose should not exceed 40 mg once daily – starting at 20 mg is recommended. Telmisartan is contraindicated in severe hepatic impairment (Child-Pugh class C) and in patients with biliary obstructive disorders, because clearance is almost entirely via biliary excretion.
Missed Dose
If you forget to take a dose, skip the missed dose and take the next dose at your usual scheduled time. Do not take a double dose to make up for the missed one, as this increases the risk of hypotension and other side effects. If you miss doses frequently, consider setting a daily reminder or linking the dose to an established routine such as brushing your teeth in the morning.
Overdose
Overdose of telmisartan may cause marked hypotension (very low blood pressure), dizziness, tachycardia (fast heart rate), bradycardia (slow heart rate), acute renal failure, or, rarely, shock. The most common signs are severe dizziness, light-headedness, and fainting. If you suspect you or someone else has taken too much Telmisartan Jubilant, seek immediate medical attention by contacting your local emergency services, poison control centre, or emergency department. Treatment is supportive: maintain airway, breathing, and circulation; place the patient in a supine position; administer intravenous saline if needed. Telmisartan is not removed by haemodialysis.
Stopping Telmisartan Jubilant
Do not stop taking telmisartan without consulting your doctor. Although there is no typical "withdrawal syndrome" with ARBs, sudden discontinuation can cause a gradual return to pre-treatment blood pressure levels, potentially increasing cardiovascular risk. If your doctor decides to discontinue telmisartan, they may switch you to an alternative antihypertensive or monitor blood pressure until the decision is finalised.
What Are the Side Effects of Telmisartan Jubilant?
The most common side effects of telmisartan are dizziness and upper respiratory tract infections. Overall, telmisartan is very well tolerated, with a side-effect profile similar to placebo in clinical trials. Serious side effects such as angioedema, severe hypotension, or hyperkalaemia are uncommon but require immediate medical attention.
Like all medicines, Telmisartan Jubilant can cause side effects, although not everybody gets them. The frequency classification used here follows the Council for International Organizations of Medical Sciences (CIOMS) convention, which is the international standard for summarising clinical-trial safety data.
- Swelling of the face, lips, tongue, or throat, or difficulty breathing (angioedema) – this can be life-threatening and may occur even after long-term use
- Severe skin reactions with extensive rash, blisters, or peeling (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Severe hypotension with dizziness, fainting, or loss of consciousness
- Signs of sepsis, such as high fever, rapid heart rate, and feeling very unwell
- Yellowing of the skin or eyes, dark urine, severe abdominal pain (signs of liver problems)
- Irregular or fast heartbeat
- Significant decrease in urine output (possible acute kidney injury)
Very Common
May affect more than 1 in 10 people
- None reported at very common frequency in clinical trials of telmisartan
Common
May affect up to 1 in 10 people
- Dizziness, particularly postural (when standing up)
- Upper respiratory tract infections (including sinusitis, pharyngitis)
- Urinary tract infections (including cystitis)
- Back pain and musculoskeletal pain
- Abdominal pain, diarrhoea, flatulence
- Hypertension control-related symptoms
Uncommon
May affect up to 1 in 100 people
- Bradycardia (slow heart rate)
- Hypotension, orthostatic hypotension
- Anaemia
- Hyperkalaemia (raised blood potassium)
- Insomnia, depression, anxiety
- Syncope (fainting)
- Vertigo
- Dyspnoea (shortness of breath), cough
- Nausea, vomiting, dyspepsia
- Pruritus, rash, hyperhidrosis (excessive sweating)
- Myalgia (muscle pain), muscle cramps
- Renal impairment, including acute renal failure
- Chest pain, weakness, fatigue
- Elevated serum creatinine
Rare and Very Rare
May affect up to 1 in 1,000 people or fewer
- Eosinophilia, thrombocytopenia
- Sepsis (including fatal cases)
- Anaphylactic reactions, angioedema (including fatal cases)
- Hypoglycaemia (in diabetic patients)
- Visual disturbances
- Tachycardia
- Interstitial lung disease
- Stomach discomfort, dry mouth, taste disturbance
- Abnormal liver function, hepatitis (more frequent in Japanese populations)
- Erythema, urticaria, drug eruption, toxic skin reaction
- Arthralgia (joint pain), tendon pain
- Elevated uric acid, elevated creatine phosphokinase, elevated liver enzymes
- Flu-like illness
Clinical trials have consistently shown that the overall frequency of side effects with telmisartan is similar to that of placebo. Importantly, telmisartan is significantly less likely than ACE inhibitors to cause a persistent dry cough, because it does not interfere with the breakdown of bradykinin. Angioedema has been reported very rarely, including in patients who previously developed angioedema on an ACE inhibitor; caution is warranted in this subgroup.
If you experience any side effects not listed here, or if any side effect becomes severe or persistent, contact your doctor or pharmacist. In the EU, you can also report suspected side effects via the national adverse-event reporting system of your country (e.g. the Yellow Card Scheme in the UK, the MedWatch system in the US). Reporting helps ensure continued monitoring of the drug's benefit-risk balance.
How Should You Store Telmisartan Jubilant?
Store Telmisartan Jubilant tablets at room temperature below 30°C in the original packaging, away from moisture and light. Keep out of the reach and sight of children. Do not use the tablets after the expiry date printed on the packaging.
Telmisartan is moisture-sensitive, which is why it is packaged in aluminium blister strips designed to protect the tablets from humidity. Keep the tablets in the original blister until just before you take them. Do not transfer the tablets to a pillbox or separate container, as this can reduce the drug's stability. Check the expiry date (marked "EXP" on the carton and blister) before taking any tablets; the expiry date refers to the last day of the stated month.
Do not use Telmisartan Jubilant if you notice any visible signs of deterioration such as discolouration, crumbling, or unusual odour. Do not flush unused or expired medication down the toilet or pour it down the drain, as this can contaminate water supplies. Return any unused or expired tablets to your pharmacy for safe disposal, which protects the environment from pharmaceutical contamination.
Keep this medicine out of the sight and reach of children. Accidental ingestion of telmisartan by a child can cause serious, potentially life-threatening hypotension.
What Does Telmisartan Jubilant Contain?
Each Telmisartan Jubilant 20 mg tablet contains the active ingredient telmisartan 20 mg and several inactive ingredients (excipients) necessary for tablet manufacture and stability.
Active Ingredient
The active substance is telmisartan. Each tablet of Telmisartan Jubilant 20 mg contains 20 mg telmisartan as the free base. Telmisartan is a non-peptide, highly selective angiotensin II type 1 (AT1) receptor antagonist.
Inactive Ingredients (Excipients)
The excipients typically used in telmisartan tablets include: meglumine (a solubiliser necessary for formulation), sodium hydroxide, povidone, mannitol, magnesium stearate, sorbitol, and lactose monohydrate or other pharmaceutical-grade fillers. These excipients ensure proper tablet formation, disintegration, stability, and absorption. For the specific excipient list of Telmisartan Jubilant 20 mg, consult the patient information leaflet supplied with the medicine.
Important Excipient Information
- Sorbitol: Patients with hereditary fructose intolerance should not take this medicine
- Lactose: If your formulation contains lactose, patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine
- Sodium content: Telmisartan tablets are generally considered "essentially sodium-free" (less than 1 mmol / 23 mg sodium per tablet), which is relevant for patients on a sodium-restricted diet
Tablet Appearance and Packaging
20 mg tablets: Appearance varies by manufacturer; typical descriptions include white to off-white, oblong or round biconvex tablets, possibly with a score line or embossed identifier.
Available in blister packs of various sizes (e.g. 14, 28, 30, 56, 98 tablets). Not all pack sizes may be marketed in every country. Check the pharmacy label for the specific presentation dispensed to you.
How Does Telmisartan Jubilant Work in the Body?
Telmisartan selectively blocks the AT1 receptor for angiotensin II, preventing the hormone from causing blood vessels to constrict and from stimulating aldosterone release. Its half-life of approximately 24 hours – the longest of any ARB – provides smooth, sustained 24-hour blood pressure control.
The renin-angiotensin-aldosterone system (RAAS) plays a central role in regulating blood pressure, fluid balance, and electrolyte homeostasis. When blood pressure drops or sodium levels fall, the kidneys secrete the enzyme renin, which converts angiotensinogen (made by the liver) into angiotensin I. Angiotensin I is then rapidly converted by angiotensin-converting enzyme (ACE) into angiotensin II, the principal effector molecule of the RAAS.
Angiotensin II exerts its effects primarily through the AT1 receptor, which is widely distributed in the vasculature, kidneys, heart, and brain. Activation of AT1 causes powerful vasoconstriction (narrowing of blood vessels), stimulation of aldosterone release from the adrenal cortex (leading to sodium and water retention), sympathetic nervous system activation, cardiac and vascular remodelling, and promotion of thirst.
Telmisartan is a highly selective, non-peptide, and insurmountable AT1 antagonist. It binds tightly to the AT1 receptor and displaces angiotensin II, preventing it from exerting its effects. The AT2 receptor, which mediates some counter-regulatory vasodilator and antiproliferative effects, remains unopposed, which may contribute favourably to telmisartan's pharmacological profile. Unlike ACE inhibitors, telmisartan does not block bradykinin degradation, which is why dry cough and angioedema – both partly mediated by bradykinin accumulation – occur very rarely with telmisartan.
Pharmacokinetic Profile
Telmisartan is absorbed rapidly after oral administration, with peak plasma concentrations reached approximately 0.5–1 hour after dosing. The absolute bioavailability is around 50% and shows dose-proportional behaviour, though there is some non-linearity at higher doses. Food intake reduces the AUC (area under the concentration-time curve) by 6–20%, which is not clinically significant.
Plasma protein binding is very high (>99.5%), mainly to albumin and alpha-1 acid glycoprotein. Telmisartan has a very large apparent volume of distribution (~500 L), indicating extensive tissue distribution. It is metabolised by glucuronidation to a pharmacologically inactive acyl-glucuronide conjugate and is excreted almost entirely (>97%) unchanged in the faeces via biliary excretion. Renal excretion is negligible (<1%). Because telmisartan is not metabolised by the CYP450 enzyme system, interactions with CYP inhibitors and inducers are generally not clinically significant.
The terminal elimination half-life is approximately 24 hours, which is the longest of any currently marketed angiotensin receptor blocker. This long half-life allows reliable once-daily dosing and provides smooth blood pressure control across the 24-hour dosing interval, with a trough-to-peak ratio greater than 80% at doses of 40–80 mg. Steady-state plasma concentrations are achieved within 5–7 days of starting therapy.
Additional Pharmacology: Partial PPAR-γ Activation
Telmisartan is a unique ARB that, in addition to blocking the AT1 receptor, has been shown in vitro and in some clinical studies to act as a partial agonist of the nuclear receptor PPAR-γ (peroxisome proliferator-activated receptor gamma), a target of the thiazolidinedione class of insulin-sensitising drugs. At clinically relevant concentrations, this activity is modest and telmisartan is not licensed for the treatment of diabetes, but it may contribute to favourable effects on insulin sensitivity, glucose tolerance, and lipid profile observed in some patients. These effects are most clinically relevant in patients with metabolic syndrome or type 2 diabetes.
Frequently Asked Questions About Telmisartan Jubilant
Telmisartan Jubilant is used to treat essential hypertension (high blood pressure) in adults and to reduce cardiovascular morbidity in patients aged 55 years and older at high risk of cardiovascular events. It is an angiotensin II receptor blocker (ARB) that works by relaxing blood vessels so blood can flow more easily, reducing the workload on the heart and lowering the risk of stroke, heart attack, and cardiovascular death. The 20 mg strength is typically used as a starting dose for sensitive patients or for gradual dose titration.
Telmisartan begins to lower blood pressure within 3 hours of the first oral dose. Because telmisartan has the longest half-life of any angiotensin receptor blocker (approximately 24 hours), its full antihypertensive effect develops gradually over 4 to 8 weeks of continuous treatment. Most patients achieve steady-state blood pressure control after 4 weeks, though some may require longer. Continue taking the medication daily even if you feel well, as high blood pressure often has no symptoms.
The most commonly reported side effects of telmisartan are dizziness (particularly when standing up quickly), upper respiratory tract infections such as sinusitis, urinary tract infections, back pain, and abdominal pain. Most side effects are mild and self-limiting. Unlike ACE inhibitors, telmisartan very rarely causes a dry cough, making it particularly suitable for patients who cannot tolerate ACE inhibitors. Serious side effects such as angioedema, severe hypotension, or hyperkalaemia are uncommon but require immediate medical attention.
No. Telmisartan Jubilant is contraindicated during the second and third trimesters of pregnancy because angiotensin II receptor blockers can cause serious harm to the developing fetus, including kidney failure, oligohydramnios, skull ossification defects, and death. Use during the first trimester is also not recommended. Women of childbearing age should use effective contraception while taking telmisartan. If you become pregnant or are planning pregnancy, contact your doctor immediately so that an alternative blood pressure medication with a better-established safety profile can be prescribed (e.g. labetalol, nifedipine modified-release, or methyldopa).
Yes. Telmisartan is frequently combined with thiazide diuretics (such as hydrochlorothiazide) or calcium channel blockers (such as amlodipine) to achieve better blood pressure control, and fixed-dose combinations are widely available. However, dual blockade of the renin-angiotensin system by combining telmisartan with an ACE inhibitor or with aliskiren is generally not recommended because of the increased risk of hypotension, hyperkalaemia, and worsening kidney function. Always consult your doctor before adding or stopping any medication.
Dizziness from telmisartan is usually due to its blood pressure-lowering effect, especially in the first few days of treatment, after a dose increase, or when standing up quickly (postural hypotension). It is more likely if you are dehydrated, on a low-salt diet, taking diuretics, or if you have heart failure. To reduce dizziness, stand up slowly from a sitting or lying position, maintain adequate fluid intake, and avoid alcohol. Persistent or severe dizziness should be reported to your doctor, who may adjust your dose.
Very rarely. Dry cough is a well-known side effect of ACE inhibitors (such as ramipril, lisinopril, and enalapril) because they prevent the breakdown of bradykinin, a substance that can irritate the airways. Telmisartan and other angiotensin receptor blockers do not inhibit bradykinin metabolism and therefore cause dry cough at rates similar to placebo. If you developed a cough on an ACE inhibitor, telmisartan is typically a well-tolerated alternative that provides similar cardiovascular protection.
Small amounts of alcohol are generally compatible with telmisartan, but excessive or binge drinking should be avoided. Alcohol itself can raise blood pressure over time and in the short term can also cause additional blood pressure lowering when combined with antihypertensive medications, increasing the risk of dizziness and falls. Limit alcohol intake to within your country's recommended safe limits, stay well hydrated, and avoid drinking alcohol at the same time as taking your dose.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248.
- The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317
- Yusuf S, Diener HC, Sacco RL, et al (PRoFESS Study Group). Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine. 2008;359(12):1225–1237. doi:10.1056/NEJMoa0804593
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2022.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Telmisartan – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66(1):51–83.
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension. 2004;43(5):993–1002.
- British National Formulary (BNF). Telmisartan. NICE BNF monograph. Accessed January 2026.
- US Food and Drug Administration (FDA). Telmisartan – Prescribing Information. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in cardiology, clinical pharmacology, and internal medicine.
Medical Writers
Board-certified physicians specialising in cardiovascular medicine and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ESC, AHA, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.